公开(公告)号：US20240197904A1

公开(公告)日：2024-06-20

申请号：US18288108

申请日：2022-04-25

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Timothy F. Cloughesy ,  Elizabeth Fernandez

IPC: A61K47/68 ,  A61K31/495 ,  A61K31/519 ,  A61N5/10 ,  A61P35/00

CPC classification number: A61K47/6849 ,  A61K31/495 ,  A61K31/519 ,  A61K47/6803 ,  A61P35/00 ,  A61N5/10

Abstract: The present disclosure relates to a method of treating a glioblastoma by conjointly administering to a subject an antibody-drug conjugate comprising a BCL-xL inhibitor and a second therapy such as an alkylating agent, irradiation, or an MCL-1 inhibitor.

公开(公告)号：US20230115366A1

公开(公告)日：2023-04-13

申请号：US17853573

申请日：2022-06-29

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Michael E. Jung ,  Jonathan Tsang ,  Lorenz Urner ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim

IPC: C07D491/056 ,  C07D239/94 ,  C07D239/95 ,  C07D405/04

Abstract: The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20240043390A1

公开(公告)日：2024-02-08

申请号：US18200265

申请日：2023-05-22

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Wilson X. Mai ,  Michael E. Jung ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim ,  Johathan Tsang ,  Lorenz Urner

IPC: C07D239/95 ,  A61P35/00 ,  A61K31/40 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  C07D405/10 ,  C07D491/056 ,  G01N33/50 ,  G01N33/574

CPC classification number: C07D239/95 ,  A61P35/00 ,  A61K31/40 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  C07D405/10 ,  C07D491/056 ,  G01N33/5011 ,  G01N33/57407

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20200290978A1

公开(公告)日：2020-09-17

申请号：US16651256

申请日：2018-09-26

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Wilson X. Mai ,  Michael E. Jung ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim ,  Jonathan Tsang ,  Lorenz Urner

IPC: C07D239/95 ,  G01N33/574 ,  A61K31/517 ,  C07D491/056 ,  A61K31/519 ,  C07D405/10 ,  G01N33/50 ,  A61K31/496 ,  A61K31/40 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20240058340A1

公开(公告)日：2024-02-22

申请号：US18027313

申请日：2021-09-20

Applicant: The Regents of the University of California ,  Erasca, Inc.

Inventor： Jean-Michel Vernier ,  David A. Nathanson ,  Michael E. Jung ,  Timothy F. Cloughesy ,  Lorenz Urner ,  Peter M. Clark ,  Jonathan Tsang

IPC: A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  A61P35/00 ,  C07D491/056 ,  C07D519/00 ,  G01N33/66

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06 ,  A61P35/00 ,  C07D491/056 ,  C07D519/00 ,  G01N33/66 ,  C07B2200/05 ,  G01N2800/52

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US20230364091A1

公开(公告)日：2023-11-16

申请号：US18027312

申请日：2021-09-20

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Michael E. Jung ,  Timothy F. Cloughesy ,  Lorenz Urner ,  Peter M. Clark ,  Jonathan Tsang

IPC: A61K31/519 ,  A61K31/496 ,  C07D491/056 ,  A61K31/5377 ,  A61K31/551 ,  C07D519/00 ,  A61K31/40 ,  A61K31/407 ,  A61K31/4439 ,  A61K31/45 ,  A61K31/711 ,  A61K31/635 ,  A61K31/4025 ,  A61K31/337 ,  A61K31/7105 ,  G01N33/66

CPC classification number: A61K31/519 ,  A61K31/496 ,  C07D491/056 ,  A61K31/5377 ,  A61K31/551 ,  C07D519/00 ,  A61K31/40 ,  A61K31/407 ,  A61K31/4439 ,  A61K31/45 ,  A61K31/711 ,  A61K31/635 ,  A61K31/4025 ,  A61K31/337 ,  A61K31/7105 ,  G01N33/66 ,  C07B2200/05

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

公开(公告)号：US09981961B2

公开(公告)日：2018-05-29

申请号：US15421258

申请日：2017-01-31

Applicant: The Regents of the University of California ,  The Board of Trustees of the University of Illinois

Inventor： Caius G. Radu ,  Zheng Li ,  Raymond M. Gipson ,  Jue Wang ,  Nagichettiar Satyamurthy ,  Arnon Lavie ,  Jennifer M. Murphy ,  David A. Nathanson ,  Michael E. Jung

IPC: C07D417/14 ,  A61K31/506 ,  C07D417/12 ,  C07B59/00 ,  A61K31/426 ,  A61K31/513 ,  A61K31/44

CPC classification number: C07D417/14 ,  A61K31/426 ,  A61K31/44 ,  A61K31/506 ,  A61K31/513 ,  C07B59/002 ,  C07B2200/05 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

Abstract: Provided herein are compounds that bind to dCK and methods for treating cancer.

公开(公告)号：US20160237076A1

公开(公告)日：2016-08-18

申请号：US14992396

申请日：2016-01-11

Applicant: The Regents of the University of California

Inventor： Caius G. Radu ,  Zheng Li ,  Raymond M. Gipson ,  Jue Wang ,  Nagichettiar Satyamurthy ,  Arnon Lavie ,  Jennifer M. Murphy ,  David A. Nathanson ,  Michael E. Jung

IPC: C07D417/12 ,  C07D413/12 ,  C07B59/00

CPC classification number: C07D417/14 ,  A61K31/426 ,  A61K31/44 ,  A61K31/506 ,  A61K31/513 ,  C07B59/002 ,  C07B2200/05 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

Abstract: Provided herein are compounds that bind to dCK and methods for treating cancer.

Abstract translation: 本文提供了结合dCK的化合物和治疗癌症的方法。

公开(公告)号：US20220213504A1

公开(公告)日：2022-07-07

申请号：US17609496

申请日：2020-05-20

Applicant: The Regents of the University of California

Inventor： Vaithilingaraja Arumugaswami ,  Gustavo Garcia, JR. ,  David A. Nathanson ,  Ren Sun

IPC: C12N15/86 ,  C07K14/005 ,  A61K39/00 ,  A61P35/00

Abstract: Disclosed herein are Zika virus constructs and methods of using Zika virus constructs and Zika viruses to treat subjects in need thereof.

公开(公告)号：US11377451B2

公开(公告)日：2022-07-05

申请号：US17475144

申请日：2021-09-14

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Michael E. Jung ,  Jonathan Tsang ,  Lorenz Urner ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim

IPC: C07D491/14 ,  C07D491/056 ,  C07D239/95 ,  C07D239/94 ,  C07D405/04

Abstract: The present disclosure relates to compounds, compositions and methods for treating cancer, including compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating cancer in the brain, including glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating cancers such as glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.